# Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Article · Darren K. McGuire, Nikolaus Marx, Sharon L. Mulvagh, John Eric Deanfield, Silvio E. Inzucchi, Rodica Pop‐Busui, Johannes F.E. Mann, Scott S. Emerson, Neil R Poulter, Mads D.M. Engelmann, Maria Sejersten Ripa, G. Kees Hovingh, Kirstine Brown‐Frandsen, Stephen Charles Bain, Matthew Aaron Cavender, Mette Gislum, Jens‐Peter David, John B. Buse

- Archive id: doi:10.1056/nejmoa2501006
- Published: 2025-03-29
- Venue: New England Journal of Medicine
- DOI: https://doi.org/10.1056/nejmoa2501006
- PMID: 40162642
- Citations: 415
- Source URL: https://doi.org/10.1056/nejmoa2501006
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.